Both in Biotechnology
PharmaCyte Biotech vs AIM ImmunoTech
Over the past year PMCB returned −67.5% and AIM returned −92.6%; their daily moves had a correlation of 0.07.
PMCB −67.5% AIM −92.6%Growth of $1, one year, split-adjusted
| Metric | PMCB | AIM |
|---|---|---|
| Price | $0.3021 | $0.1545 |
| Market cap | $3.2M | $6.2M |
| Today | −9.03% | −4.04% |
| 1 month | −25.2% | −17.7% |
| 6 months | −60.0% | −70.0% |
| Year to date | −58.3% | −86.3% |
| 1 year | −68.5% | −93.5% |
| Revenue growth (YoY) | — | +4.0% |
| Gross margin | — | 80.8% |
| Net margin | — | −26876.9% |
| P/E (TTM) | — | — |
| Price / sales | — | 64.9× |
| Net cash | $30.5M | $6.3M |
| Dividend yield | — | — |
| Volatility (60d) | 63.8% | 70.1% |
| Short % of float | 0.8% | 3.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).